- Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer
-
Uno M, Matsuo R, Maezawa N, Kato T
- KMID: 2544384
- Obstet Gynecol Sci.
- 2023 Jul;66(4):290-299.
- doi: 10.5468/ogs.23024
Objective We evaluated the usefulness of human epididymis protein 4 (HE4), a tumor marker, during and after treatment in patients with ovarian cancer (OC). Methods We included Japanese patients newly diagnosed... -
- CITED
-
- Close
- SHARE
-
- Close
- The baseline recurrence risk of patients with intermediate-risk cervical cancer
-
Yoneoka Y, Kato MK, Tanase Y, Uno M, Ishikawa M, Murakami T, Kato T
- KMID: 2513952
- Obstet Gynecol Sci.
- 2021 Mar;64(2):226-233.
- doi: 10.5468/ogs.20243
Objective This study aimed to investigate the prognosis of patients with intermediate-risk cervical cancer and to evaluate the necessity of adjuvant therapy. Methods We conducted a retrospective chart review of patients with stage... -
- CITED
-
- Close
- SHARE
-
- Close
- High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer
-
Yazaki S, Kojima Y, Yoshida H, Takamizawa S, Kitadai R, Nishikawa T, Shimoi T, Sudo K, Saito A, Okuma HS, Tanioka M, Noguchi E, Uno M, Ishikawa M, Kato T, Fujiwara Y, Ohe Y, Yonemori K
- KMID: 2537963
- J Gynecol Oncol.
- 2022 Nov;33(6):e82.
- doi: 10.3802/jgo.2022.33.e82
Objective Folate receptor α (FRα) is a membrane protein expressed in various solid tumors but has limited expression in normal cells. Therefore, FRα is an attractive target for cancer treatment. This... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
-
Yoneoka Y, Ishikawa M, Uehara T, Shimizu H, Uno M, Murakami T, Kato T
- KMID: 2457157
- J Gynecol Oncol.
- 2019 Sep;30(5):e81.
- doi: 10.3802/jgo.2019.30.e81
OBJECTIVE: To treat advanced ovarian cancer, interval debulking surgery (IDS) is performed after 3 cycles each of neoadjuvant chemotherapy (NAC) and postoperative chemotherapy (IDS group). If we expect that complete... -
- CITED
-
- Close
- SHARE
-
- Close
